Dose predictions for [(177)Lu]Lu-DOTA-panitumumab F(ab′)(2) in NRG mice with HNSCC patient-derived tumour xenografts based on [(64)Cu]Cu-DOTA-panitumumab F(ab′)(2) – implications for a PET theranostic strategy

BACKGROUND: Epidermal growth factor receptors (EGFR) are overexpressed on many head and neck squamous cell carcinoma (HNSCC). Radioimmunotherapy (RIT) with F(ab')(2) of the anti-EGFR monoclonal antibody panitumumab labeled with the β-particle emitter, (177)Lu may be a promising treatment for HN...

Descripción completa

Detalles Bibliográficos
Autores principales: Ku, Anthony, Kondo, Misaki, Cai, Zhongli, Meens, Jalna, Li, Min Rong, Ailles, Laurie, Reilly, Raymond M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360260/
https://www.ncbi.nlm.nih.gov/pubmed/34383182
http://dx.doi.org/10.1186/s41181-021-00140-1

Ejemplares similares

Ejemplares similares